JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De Luca, A.
Right arrow Articles by Camerino, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Luca, A.
Right arrow Articles by Camerino, D. C.

Vol. 282, Issue 1, 93-100, 1997

Evaluation of the Antimyotonic Activity of Mexiletine and Some New Analogs on Sodium Currents of Single Muscle Fibers and on the Abnormal Excitability of the Myotonic ADR Mouse1

Annamaria De Luca, Sabata Pierno, Fedele Natuzzi, Carlo Franchini, Andrea Duranti, Giovanni Lentini, Vincenzo Tortorella, Harald Jockusch and Diana Conte Camerino

Unit of Pharmacology, Department of Pharmacobiology (A.D.L., S.P., F.N., D.C.C.), and Department of Medicinal Chemistry (C.F., A.D., G.L., V.T.), Faculty of Pharmacy, University of Bari, 70125 Italy, and Developmental Biology Unit (H.J.), W7, University of Bielefeld, D-33501, Germany

To search for use-dependent sodium channel blockers to selectively solve skeletal muscle hyperexcitability in hereditary myotonias, mexiletine (MEX; compound I) and its newly synthetized analogs, 2-(4-chloro-2-methylphenoxy)-benzenethanamine (compound II) and (-)-S-3-(2,6-dimethylphenoxy)-2-methylpropanamine (compound III), were tested on intercostal muscle fibers from the myotonic ADR mouse through use of the standard current-clamp microelectrode technique. In parallel, the effects of these compounds on the sodium channels were measured on frog muscle fibers under voltage-clamp conditions. The tonic and use-dependent blocks of peak sodium currents (INamax) produced by each compound were evaluated by using a single depolarizing pulse and a pulse train at 10 Hz frequency, respectively. At 10 and 50 µM, MEX decreased the occurrence of spontaneous excitability in myotonic muscle fibers; 100 µM was required to decrease the amplitude of the action potential and the stimulus-induced firing of the membrane as well as to increase the threshold for generation of action potential. At 300 µM, MEX decreased the latency of the action potential and increased the threshold current to elicit a single action potential. MEX produced a tonic block of INamax with an half-maximal concentration (IC50) of 83 µM, but the IC50 value for use-dependent block was 3-fold lower. Compound III, which differs from MEX in that it has a longer alkyl chain, similarly blocked first the spontaneous and then the stimulus-evoked excitability of myotonic muscle fibers but at 2-fold lower concentrations than MEX. Compound III was less potent than MEX in producing a tonic block of INamax (IC50 = 108 µM) but was a strong use-dependent blocker with an IC50 close to 15 µM. The more lipophylic compound II irreversibly blocked both spontaneous and stimulus-evoked membrane excitability at concentrations as low as 10 µM and shortened the latency of the action potential in a concentration-dependent fashion. Compound II produced a potent tonic block of INamax (IC50 = 30 µM), and its potency increased 2-fold during high-frequency stimulation. Both of the new analogs (compound II in particular), but not MEX, were less effective on the excitability parameters of striated fibers of healthy vs. ADR mice, a characteristic that increases their interest as potential antimyotonic agents.


Copyright © by The American Society for Pharmacology and Experimental Therapeutics






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.